Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects

• Published in: Nutrition & metabolism Vol. 8; no. 1; pp. 7 - 310
• Main Authors: Banni, Sebastiano, Carta, Gianfranca, Murru, Elisabetta, Cordeddu, Lina, Giordano, Elena, Sirigu, Anna Rita, Berge, Kjetil, Vik, Hogne, Maki, Kevin C, Di Marzo, Vincenzo, Griinari, Mikko
• Format: Journal Article
• Language: English
• Published: London BioMed Central 30.01.2011; BioMed Central Ltd; BMC
• Subjects: Arachidonic acid; biosynthesis; Blood pressure; Clinical Nutrition; Diet; Essences and essential oils; Health aspects; humans; Inflammatory bowel disease; Insulin resistance; Krill; Lipids; long chain polyunsaturated fatty acids; Medicine; Medicine & Public Health; menhaden oil; Metabolic Diseases; metabolic syndrome; Nutrition; Obesity; olive oil; phospholipids; Physiological aspects; rats; Studies; Triglycerides; Norway; United States; Italy; Obese Subject; Rimonabant; Visceral Adipose Tissue; Plasma Phospholipid; Anandamide
• ISSN: 1743-7075; 1743-7075
• DOI: 10.1186/1743-7075-8-7

We have previously shown that krill oil (KO), more efficiently than fish oil, was able to downregulate the endocannabinoid system in different tissues of obese zucker rats. We therefore aimed at investigating whether an intake of 2 g/d of either KO or menhaden oil (MO), which provides 309 mg/d of EPA/DHA 2:1 and 390 mg/d of EPA/DHA 1:1 respectively, or olive oil (OO) for four weeks, is able to modify plasma endocannabinoids in overweight and obese subjects. The results confirmed data in the literature describing increased levels of endocannabinoids in overweight and obese with respect to normo-weight subjects. KO, but not MO or OO, was able to significantly decrease 2-arachidonoylglycerol (2-AG), although only in obese subjects. In addition, the decrease of 2-AG was correlated to the plasma n-6/n-3 phospholipid long chain polyunsaturated fatty acid (LCPUFA) ratio. These data show for the first time in humans that relatively low doses of LCPUFA n-3 as KO can significantly decrease plasma 2-AG levels in obese subjects in relation to decrease of plasma phospholipid n-6/n-3 LCPUFA ratio. This effect is not linked to changes of metabolic syndrome parameters but is most likely due to a decrease of 2-AG biosynthesis caused by the replacement of 2-AG ultimate precursor, arachidonic acid, with n-3 PUFAs, as previously described in obese Zucker rats.